Guardant Health (NASDAQ:GH) Given Buy Rating at Guggenheim

Guggenheim reissued their buy rating on shares of Guardant Health (NASDAQ:GH) in a research report sent to investors on Monday,Benzinga reports. They currently have a $56.00 target price on the stock.

Several other analysts have also recently commented on the company. Sanford C. Bernstein decreased their target price on Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, October 30th. Stifel Nicolaus boosted their price target on Guardant Health from $45.00 to $53.00 and gave the company a “buy” rating in a research note on Friday. Barclays assumed coverage on Guardant Health in a research note on Thursday, January 23rd. They set an “overweight” rating and a $60.00 price target on the stock. The Goldman Sachs Group boosted their price target on Guardant Health from $49.00 to $56.00 and gave the company a “buy” rating in a research note on Friday. Finally, Canaccord Genuity Group upped their price objective on Guardant Health from $42.00 to $60.00 and gave the company a “buy” rating in a research note on Monday. Nineteen investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $47.37.

Guardant Health Price Performance

Shares of Guardant Health stock opened at $42.44 on Monday. Guardant Health has a 1-year low of $15.81 and a 1-year high of $50.89. The company has a market capitalization of $5.24 billion, a P/E ratio of -11.92 and a beta of 1.32. The business’s fifty day moving average price is $40.32 and its two-hundred day moving average price is $31.66.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The firm had revenue of $201.81 million for the quarter, compared to analyst estimates of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. On average, research analysts expect that Guardant Health will post -2.9 earnings per share for the current fiscal year.

Insider Buying and Selling at Guardant Health

In related news, Director Musa Tariq sold 2,320 shares of the company’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the sale, the director now owns 2,676 shares in the company, valued at $93,660. This represents a 46.44 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders sold 2,768 shares of company stock worth $98,798. Insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Guardant Health

A number of large investors have recently added to or reduced their stakes in GH. NewEdge Advisors LLC boosted its stake in shares of Guardant Health by 13.5% during the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company’s stock worth $59,000 after buying an additional 230 shares during the last quarter. Summit Investment Advisors Inc. boosted its stake in shares of Guardant Health by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 12,346 shares of the company’s stock worth $377,000 after buying an additional 391 shares during the last quarter. Arizona State Retirement System boosted its stake in shares of Guardant Health by 1.1% during the 4th quarter. Arizona State Retirement System now owns 35,639 shares of the company’s stock worth $1,089,000 after buying an additional 403 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Guardant Health by 21.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company’s stock worth $102,000 after buying an additional 796 shares during the last quarter. Finally, Jones Financial Companies Lllp boosted its stake in shares of Guardant Health by 43.5% during the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock worth $82,000 after buying an additional 817 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.